Janssen Biotech, Inc., a Johnson & Johnson company, has entered into a definitive agreement to acquire BeneVir Biopharm, Inc., a privately-held company specializing in the development of oncolytic immunotherapies for as much as $1 billion. The transaction, subject to customary closing conditions, is expected to close in the second quarter of 2018. BeneVir uses its T-Stealth Oncolytic Virus Platform to engineer oncolytic viruses tailored to infect and destroy cancer cells. Janssen in...